Chemical Instability in Peptide and Protein Pharmaceuticals

Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals

Volumn , Issue , 2010, Pages 41-67

  Topp, Elizabeth M ^a   Zhang, Lei ^a   Zhao, Hong ^a   Payne, Robert W ^b   Evans, Gabriel J ^b   Manning, Mark Cornell ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b Legacy BioDesign LLC   (United States)

Author keywords

Condensation reaction, molecules combining covalently linked products with elimination of small molecule; Metal catalyzed oxidation (MCO) and free radical oxidation; Peptide and protein pharmaceutical chemical instability

Indexed keywords

EID: 84886023195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470595886.ch2     Document Type: Chapter

References (188)

1. Manning, M. C., Patel, K., and Borchardt, R. T. (1989), Stability of protein pharmaceuticals, Pharm. Res., 6: 903-918.
2. Wang, W., Singh, S., Zeng, D. L., King, K., and Nema, S. (2007), Antibody structure, instability, and formulation, J. Pharm. Sci., 96: 1-26.
3. Liu, H., Gaza-Bulseco, G., Faldu, D., Chumsae, C., and Sun, J. (2008), Heterogeneity of monoclonal antibodies, J. Pharm. Sci. 97: 2426-2447.
4. Aswad, D. W., ed. (1995), Deamidation and Isoaspartate Formation in Peptides and Proteins, CRC Press, Boca Raton, FL.
5. Robinson, N. E. and Robinson, A. B. (2004), Molecular Clocks: Deamidation of Asparaginyl and Glutaminyl Residues in Peptides and Proteins, Althouse Press, Cave Junction, OR.
6. Wright, H. T. (1991), Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins, Crit. Rev. Biochem. Mol. Biol. 26: 1-52.
7. Lai, M. C. and Topp, E. M. (1999). Solid-state chemical stability of proteins and peptides, J. Pharm. Sci. 88: 489-500.
8. Reissner, K. J. and Aswad, D. W. (2003), Deamidation and isoaspartate formation in proteins: Unwanted alterations or surreptitious signals? Cell. Mol. Life Sci. 60: 1281-1295.
9. Wakanar, A. A. and Borchardt, R. T. (2006), Formulation considerations for proteins susceptible to asparagines deamidation and aspartate isomerization, J. Pharm. Sci. 95: 2321-2336.
10. Barnes, C. A. S. and Lim, A. (2007), Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals, Mass Spectrom. Rev. 26: 370-388.
11. Chu, G. L., Chelius, D., Xiao, G., Khor, H. K., Coulibaly, S., and Bondarenko, P. V. (2007), Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures, Pharm. Res. 24: 1145-1156.
12. Clarke, S., Stephenson, R. C., and Lowenson, J. D. (1992), Lability of asparagine and aspartic acid residues in proteins and peptides, in Stability of Protein Pharmaceuticals, Part A: Chemical and Physical Pathways of Protein Degradation, Ahern, T. J. and Manning, M. C., eds., Plenum Press, New York, pp. 1-29.
13. Catak, S., Monard, G., Aviyente, V., and Ruiz-Lopez, M. F. (2006), Reaction mechanism of deamidation of asparaginyl residues in peptides: Effect of solvent molecules, J. Phys. Chem. A, 110: 8354-8365.
14. Heaton, A. L. and Armentrout, P. B. (2008), Thermodynamics and mechanism of the deamidation of sodium-bound asparagine, J. Am. Chem. Soc. 130: 10227-10232.
15. Catak, S., Monard, G., Aviyente, V., and Ruiz-Lopez, M. F. (2008), Computational study on nonenzymatic peptide bond cleavage at asparagine and aspartic acid, J. Phys. Chem. A 112: 8752-8761.
16. Kossiakoff, A. A. (1988), Tertiary structure is a principal determinant to protein deamidation. Science 240: 191-194.
17. Xie, M., Shahrokh, Z., Kadkhhodayan, M., Henzel, W. J., Powell, M. F., Borchardt, R. T., and Schowen, R. L. (2003), Asparagine deamidation in recombinant human lymphotoxin: Hindrance by three-dimensional structures, J. Pharm. Sci. 92: 869-880.
18. Capasso, S. and Salvadori, S. (1999), Effect of the three-dimensional structure on the deamidation reaction of ribonuclease A, J. Pept. Res. 54: 377-382.
19. Capasso, S. and Di Cerbo, P. (2000), Kinetic and thermodynamic control of the relative yield of the deamidation of asparagine and isomerization of aspartic acid residues, J. Pept. Res. 56: 382-387.
20. Stevenson, C. L., Donlan, M. E., Friedman, A. R., and Borchardt, R. T. (1993), Solution conformation of LEU27 HGRF (1-32) NH2 and its deamidation products by 2D NMR. Int. J. Pept. Protein Res. 42: 24-32.
21. Rivers, J., McDonald, L., Edwards, I. J., and Beynon, R. J. (2008), Asparagine deamidation and the role of higher order protein structure, J. Proteome Res. 7: 921-927.
22. Xie, M., Aube, J., Borchardt, R. T., Morton, M., Topp, E. M., Vander Velde, D., and Schowen, R. L. (2000), Reactivity toward deamidation of asparagine residues in beta-turn structures. J. Pept. Res. 56: 165-171.
23. Patel, K. and Borchardt, R. T. (1990), Deamidation of asparaginyl residues in proteins: A potential pathway for chemical degradation of proteins in lyophilized dosage forms, J. Parenter. Sci. Technol. 44: 300-310.
24. Tyler-Cross, R. and Schirch, V. (1991), Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides, J. Biol. Chem. 226: 22549-22556.
25. Zheng, J. Y. and Janis, L. J. (2006), Influence of pH, buffer species, and storage temperature on physiochemical stability of a humanized monoclonal antibody LA298, Int. J. Pharm. 308: 46-51.
26. Brange, J. (1992), Chemical stability of insulin. 4. Mechanisms and kinetics of chemical transformations in pharmaceutical formulation, Acta Pharm. Nordica 4: 209-222.
27. Fisher, B. V. and Porter, P. B. (1981), Stability of bovine insulin, J. Pharm. Pharmacol. 33: 203-206.
28. Klotz, A. V. and Thomas, B. A. (1993), N5-Methylasparagine and asparagine as nucleophiles in peptides: Main-chain vs. side-chain amide cleavage, J. Org. Chem. 58: 6985-6989.
29. Stratton, L. P., Kelly, R. M., Rowe, J., Shively, J. E., Smith, D. D., Carpenter, J. F., and Manning, M. C. (2001), Controlling deamidation rates in a model peptide: effects of temperature, peptide concentration, and additives, J. Pharm. Sci. 90: 2141-2148.
30. Zhang, J., Lee, T. C., and Ho, C. T. (1993), Kinetics and mechanism of nonenzymic deamidation of soy protein, J. Food Process. Preserv., 17: 259-268.
31. Wearne, S. J. and Creighton, T. E. (1989), Effect of protein conformation on rate of deamidation- ribonuclease A, Proteins: Struct. Funct. Genet. 5: 8-12.
32. Nilsson, M. R., Driscoll, M., and Raleigh, D. P. (2002), Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study amyloid formation, Protein Sci. 11: 342-349.
33. Harms, M. J., Wilmorth, P. A., Kapfer, D. M., Steel, E. A., David, L. L., Bachinger, H. P., and Lampi, K. J. (2004), Laser light-scattering evidence for an altered association of beta B1-crystallin deamidated in the connecting peptide, Protein Sci. 13: 678-686.
34. Harn, N. R., Jeng, Y. N., Kostelc, J. G., and Middaugh, C. R. (2005), Spectroscopic analysis of highly concentrated suspensions of bovine somatotropin in sesame oil, J. Pharm. Sci. 94: 2487-2495.
35. Flaugh, S. L., Mills, I. A., and King, J. (2006), Glutamine deamidation destabilizes human V D-crystallin and lowers the kinetic barrier to unfolding, J. Biol. Chem. 281: 30782-30793.
36. Silva, T., Kirkpatrick, A., Brodsky, B., and Ramshaw, J. A. M. (2005), Effect of deamidation on stability for the collegen to gelatin transition, J. Agric. Food Chem. 53: 7802-7806.
37. Li, B., Borchardt, R. T., Topp, E. M., Vander Velde, D., and Schowen, R. L. (2003), Racemization of an asparagine residue during peptide deamidation, J. Am. Chem. Soc. 125: 11486-11487.
38. DeHart, M. P. and Anderson, B. D. (2007), The role of the cyclic imide in alternate degradation pathways for asparagine-containing peptides and proteins, J. Pharm. Sci. 96: 2667-2685.
39. Inglis, A. S. (1983), Cleavage at aspartic acid, Meth. Enzymol. 91: 324-332.
40. Goolcharran, C., Khossravi, M., and Borchardt, R. T. (2000), Chemical pathways of peptide and protein degradation, in Pharmaceutical Formulation Development of Peptides and Proteins, Frokjaer, S. and Hovgaard, L., eds., CRC Press, New York.
41. Frokjaer, S., and Otzen, D. E. (2005), Protein drug stability: A formulation challenge, Nat. Rev. Drug Discov. 4: 298-306.
42. Joshi, A. B. and Kirsch, L. E. (2002), The relative rates of glutamine and asparagine deamidation in glucagon fragment 22-29 under acidic conditions, J. Pharm. Sci. 91: 2331-2345.
43. Joshi, A. B. and Kirsch, L. E. (2004), The estimation of glutaminyl deamidation and aspartyl cleavage rates in glucagon, Int. J. Pharm. 273: 213-219.
44. Scḧoneich, C., Hageman, M. J., and Borchardt, R. T. (1997), Stability of peptide and proteins, in Controlled Drug Delivery. Challenges and Strategies, Park, K., ed., ACS Books, Washington, DC.
45. Ledvina, M. and Labella, F. S. (1970), Fluorescent substances in protein hydrolyzates 1. Acid "Hydrolyzates" of individual amino acids, Anal. Biochem. 36: 174-181.
46. Xing, D. K. L., Crane, D. T., Bolgiano, B., Corbel, M. J., Jones, C., and Sesardic, D. (1996), Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro, Vaccine 14: 1205-1213.
47. Luykx, D. M. A. M., Casteleijn, M. G., Jiskoot, W., Westdijk, J., and Jongen, D. M. J. M. (2004), Physicochemical studies on the stability of influenza haemagglutin in vaccine bulk material, Eur. J. Pharm. Sci. 23: 65-75.
48. Battersby, J. E., Hancock, W. S., Canovadavis, E., Oeswein, J., and O'Connor, B. (1994), Diketopiperazine formation and N-terminal degradation in recombinant human growthhormone, Int. J. Pept. Protein Res. 44: 215-222.
49. Fisher, P. (2003), Diketopiperazines in peptide and combinatorial chemistry, J. Pept. Sci. 9: 9-35.
50. Marsden, B. J., Nguyen, T. M. D., and Schiller, P. W. (1993), Spontaneous degradation via diketopiperazine formation of peptides containing a tetrahydroisoquinoline-3-carboxylic acid residue in the 2-position of the peptide sequence, Int. J. Pept. Protein Res. 41: 313-316.
51. Sepetov, N. F., Krymsky, M. A., Ovchinnikov, M. V., Bespalova, Z. D., Isakova, O. L., Soucek, M., and Lebl, M. (1991), Rearrangement, racemization and decomposition of peptides in aqueous solution, Pept. Res. 4: 308-313.
52. Capasso, S., Vergara, A., and Mazzarella, L. (1998), Mechanism of 2,5-dioxopiperazine formation, J. Am. Chem. Soc. 120: 1990-1995.
53. Capasso, S., Sica, F., Mazzarella, L., Balboni, G., Guerrini, R., and Salvadori, S. (1995), Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position-2, Int. J. Pept. Protein Res. 45: 567-573.
54. Capasso, S. and Mazzarella, L. (1999), Solvent effects on diketopiperazine formation from N-terminal peptide residues, J. Chem. Soc. Perkin Trans. 2 2: 329-332.
55. Kertscher, U., Bienert, M., Krause, E., Sepetov, N. F., and Mehlis, B. (1993), Spontaneous chemical degradation of substance P in the solid-phase and in solution, Int. J. Pept. Protein Res. 41: 207-211.
56. Blomback, B. (1967), Derivatives of glutamine in peptides, Meth. Enzymol. 11: 398-411.
57. Yu, L., Vizel, A., Huff, M. B., Young, M., Remmele Jr., R. L., and He, B. (2006), Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development, J. Pharm. Biomed. Anal. 42: 455-463.
58. Liu, H., Gaza-Bulseco, G., and Sun, J. (2006), Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature, J. Chrom. B 837: 35-43.
59. Chelius, D., Jing, K., Lueras, A., Rehder, D. S., Dillion, T. M., Vizel, A., Rajan, R. S., Li, T., Treuheit, M. J., and Bondarenko, P. V. (2006), Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies, Anal. Chem. 78: 2370-2376.
60. Lewis, D. A., Guzzetta, A. W., Hancock, W. S., and Costello, M. (1994), Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS, Anal. Chem. 66: 585-595.
61. Werner, W. E., Wu, S., and Mulkerrin, M. (2005), The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains, Anal. Biochem. 342: 120-125.
62. Wang, L., Amphlett, G., Blatter, W. A., Lambert, J. M., and Zhang, W. (2005), Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901- DM1, by mass spectrometry, Protein Sci. 14: 2436-2446.
63. Wang, L., Amphlett, G., Lambert, J. M., Blatter, W., and Zhang, W. (2005), Structural characterization of a recombinant monoclonal antibody by electrospray time-of -flight mass spectrometry, Pharm. Res. 22: 1338-1349.
64. Rehder, D. S., Dillion, T. M., Pipes, G. D., and Bondarenko, P. V. (2006), Reversed-phase liquid chromatography/mass spectrometry analysis of reduced monoclonal antibodies in pharmaceutics, J. Chrom. A 1102: 164-175.
65. Dick, L. W., Kim, C., Qiu, D. F., and Cheng, K. C. (2007), Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides, Biotechnol. Bioeng. 97: 544-553.
66. Busby Jr., W. H., Quackenbush, G. E., Humm, J., Youngblood, W. W., and Kizer, J. S. (1987), An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes, J. Biol. Chem. 262: 8532-8536.
67. Messer, M. (1963), Enzymatic cyclization of L-glutamine and L-glutaminyl peptides, Nature 197: 1299-.
68. Bunnett, J. F. (1962), The mechanism of bimolecular beta-elimination reactions, Angew. Chem. 1: 225-280.
69. Volkin, D. B. and Klibanov, A. M. (1987), Thermal destruction processes in proteins involving cystine residues, J. Biol. Chem. 262: 2945-2950.
70. Chatterji, T., Keerthi, K., and Gates, K. S. (2005), Generation of reactive oxygen species by a persulfide (BnSSH), Bioorg. Med. Chem. Lett. 15: 3921-3924.
71. Violand, B. N. V. and Siegel, N. R. (2000). Protein and peptide chemical and physical stability, in Peptide and Protein Drug Analysis, Reid, R. E. ed., Marcel Dekker, New York, pp. 257-284.
72. Costantino, H. R., Langer, R., and Klibanov, A. M. (1994), Solid-phase aggregation of proteins under pharmaceutically relevant conditions, J. Pharm. Sci. 83: 1662-1669.
73. Costantino, H. R., Schwendeman, S. P., Langer, R., and Klibanov, A. M. (1998), Deterioration of lyophilized pharmaceutical proteins, Biochem. (Moscow) 63: 357-363.
74. Chang, B. S., Kendrick, B. S., and Carpenter, J. F. (1996), Surface-induced denaturation of proteins during freezing and its inhibition by surfactants, J. Pharm. Sci. 85: 1325-1330.
75. Cohen, S. L., Price, C., and Vlasak, J. (2007), Beta-elimination and peptide bond hydrolysis: Two distinct mechanisms of human IgG1 hinge fragmentation upon storage, J. Am. Chem. Soc. 129: 6976-6977.
76. Gaza-Bulesco, G., and Liu, H. (2008), Fragmentation of a recombinant monoclonal antibody at various pH, Pharm. Res. 25: 1881-1890.
77. Nakamura, T., Sakai, M., Sadakane, Y., Haga, T., Goto, Y., Kinouchi, T., Saito, T., and Fujii, N. (2008), Differential rate constants of racemization of aspartyl and asparaginyl residues in human alpha A-crystallin mutants, Biochim. Biophys. Acta 1784: 1192-1199.
78. Nakamura, T., Sadakane, Y., and Fujii, N. (2006), Kinetic study of racemization of aspartyl residues in recombinant human alpha A-crystallin, Biochim. Biophys. Acta 1764: 800-806.
79. Fujii, N., Ishibashi, Y., Satoh, K., Fujino, M., and Harada, K. (1994), Simultaneous racemization and isomerization at specific aspartic acid residues in alpha B-crystallin from the aged human lens, Biochim. Biophys. Acta 1204: 157-163.
80. Sakai-Kato, K., Naito, M., and Utsunomiya-Tate, N. (2007), Racemization of the amyloidal beta Asp1 residue blocks the acceleration of fibril formation caused by racemization of the Asp23 residue, Biochem. Biophys. Res. Commun. 364: 464-469.
81. Tomiyama, T., Asano, S., Furiya, Y., Shirasawa, T., Endo, N., and Mori, H. (1994), Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues, J. Biol. Chem. 269: 10205-10208.
82. Murakami, K., Uno, M., Masuda, Y., Shimizu, T., Shirasawa, T., and Irie, K. (2008), Isomerization and/or racemization at Asp23 of Abeta-42 do not increase its aggregative ability, neurotoxicity, and radical productivity in vitro, Biochem. Biophys. Res. Commun. 366: 745-751.
83. Geiger, T. and Clarke, S. (1987), Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides- succinimide-linked reactions that contribute to protein degradation, J. Biol. Chem. 262: 785-794.
84. Radkiewicz, J. L., Zipse, H., Clarke, S., and Houk, K. N. (1996), Accelerated racemization of aspartic acid and asparagine residues via succinimide intermediates: An ab initio theoretical exploration of mechanism, J. Am. Chem. Soc. 118: 9148-9155.
85. Li, B., Borchardt, R. T., Topp, E. M., Vander Velde, D., and Schowen, R. L. (2003), Racemization of an asparagine residue during peptide deamidation, J. Am. Chem. Soc. 125: 11486-11487.
86. Schey, K. L. and Finley, E. L. (2000), Identification of peptide oxidation by tandem mass spectrometry. Acc. Chem. Res. 33: 299-306.
87. Scḧoneich, C., Zhao, F., Yang, J., and Miller, B. L. (1997), Mechanisms of methionine oxidation peptides, ACS Symp. Ser. 675: 79-89.
88. Hovorka, S. W. and Scḧoneich, C. (2001), Oxidative degradation of pharmaceuticals: Theory, mechanisms and inhibition, J. Pharm. Sci. 90: 253-269.
89. Volkin, D. B., Mach, H., and Middaugh, C. R. (1997), Degradative covalent reactions important to protein stability, Mol. Biotechnol. 8: 105-122.
90. Li, S., Scḧoneich, C., and Borchardt, R. T. (1995), Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization, Biotechnol. Bioeng. 48: 490-500.
91. Stadtman, E. R. (1990), Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences, Free Radical Biol. Med. 9: 315-325.
92. Stadtman, E. R. (1993), Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions, Annu. Rev. Biochem. 62: 797-821.
93. Nguyen, T. H. (1994), Oxidation degradation of protein pharmaceuticals, ACS Symp. Ser. 567: 59-71.
94. Chen, B., Costantino, H. R., Liu, J., Hsu, C. C., and Shire, S. J. (1999), Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease 1 in the aqueous and lyophilized states, J. Pharm. Sci. 88: 477-482.
95. Grillo, A. O., Edwards, K. T., Kashi, R. S., Shipley, K. M., Hu, L., Besman, M. J., and Middaugh, C. R. (2001), Conformational origin of the aggregation of recombinant human growth factor VIII, Biochemistry 40: 586-595.
96. Scḧoneich, C. (2000), Mechanisms of metal-catalyzed oxidation of histidine to 2-oxohistidine in peptides and proteins, J. Pharm. Biomed. Anal. 21: 1093-1097.
97. Chen, B., Bautista, R., Yu, K., Zapata, G. A., Mulkerrin, M. G., and Shamow, S. M. (2003), Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms, Pharm. Res. 20: 1952-1960.
98. Buettner, G. R. and Jurkiewicz, B. A. (1996), Catalytic metals, ascorbate and free radicals: Combinations to avoid, Rad. Res. 145: 532-541.
99. Yang, T.-H., Cleland, J. L., Lam, X., Meyer, J. D., Jones, L. S., Randolph, T. W., Manning, M. C., and Carpenter, J. F. (2000), Effect of zinc binding and precipitation on structures of recombinant human growth hormone and nerve growth factor, J. Pharm. Sci. 89: 1480-1485.
100. Cunningham, B. C., Mulkerrin, M. G., and Wells, J. A. (1991), Dimerization of human growth hormone by zinc, Science 253: 545-548.
101. Hovorka, S. W., Hong, J., Cleland, J. L., and Scḧoneich, C. (2001), Metal-catalyzed oxidation of human growth hormone: Modulation by solvent-induced changes of protein conformation, J. Pharm. Sci. 90: 58-69.
102. Zhao, F., Ghezzo-Scḧoneich, E., Aced, G. I., Hong, J., Milby, T., and Scḧoneich, C. (1997), Metal-catalyzed oxidation of histidine in human growth hormone, J. Biol. Chem. 272: 9019-9029.
103. Hovorka, S. W., Williams, T. D., and Scḧoneich, C. (2002), Characterization of the metalbinding site of bovine growth hormone through site-specific metal-catalyzed oxidation and high-performance liquid chromatography-tandem mass spectrometry, Anal. Biochem. 300: 206-211.
104. Sadineni, V., Galeva, N. A., and Scḧoneich, C. (2006), Characterization of the metalbinding site of human prolactin by site-specific metal-catalyzed oxidation, Anal. Biochem. 358: 208-215.
105. Hong, J. and Scḧoneich, C. (2001), The metal-catalyzed oxidation of methionine in peptides by Fenton systems involves two consecutive one-electron oxidation processes, Free Radical Biol. Med. 31: 1432-1441.
106. Hawkins, C. L. and Davies, M. J. (2001), Generation and propagation of radical reactions on proteins, Biochim. Biophys. Acta 1504: 196-219.
107. Kerwin, B. A., Akers, M. J., Apostol, I., Moore-Einsel, C., Etter, J. E., Hess, E., Lippincott, J., Levine, J., Mathews, A. J., Revilla-Sharp, P., Schubert, R., and Looker, D. L. (1999), Acute and long-term stability studies of deoxy hemoglobin and characterization of ascorbate-induced modifications, J. Pharm. Sci. 88: 79-88.
108. Fransson, J., Florin-Robertsson, E., Axelsson, K., and Nyhlen, C. (1996), Oxidation of human insulin-like growth factor I in formulation studies: kinetics of methionine oxidation in aqueous solution and in solid state, Pharm. Res. 13: 1252-1257.
109. Wisniewski, R. (1998), Developing large-scale cryopreservation systems for biopharmaceutical products, BioPharm (June) 50-60.
110. Griffiths, S. W., and Cooney, C. L. (2002), Relationship between protein structure and methionine oxidation in recombinant a 1-antitrypsin, Biochemistry 41: 6245-6252.
111. Duenas, E. T., Keck, R., DeVos, A., Jones, A. J. S., and Cleland, J. L. (2001), Comparison between light-induced and chemically induced oxidation of rhVEGF, Pharm. Res. 18: 1455-1460.
112. Chu, J. W., Yin, J., Wang, D. I. C., and Trout, B. L. (2004), Molecular dynamic situations and oxidation rates of methionine residues of granulocyte colony-stimulating factor at different pH values, Biochemistry 43: 1019-1029.
113. Lu, H. S., Fausset, P. R., Nahri, L. O., Horan, T., Shinagawa, K., Shimamoto, G., and Boone, T. C. (1999), Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: Effect on stability and biological activity, Arch. Biochem. Biophys. 362: 1-11.
114. Teh, L. C., Murphy, L. J., Huq, N. L., Surus, A. S, Friesen, H. G., Lazarus, L., and Chapman, G. E. (1987), Methionine oxidation in human growth hormone and human chorionic somatomammotropin. Effects on receptor binding and biological activities, J. Biol. Chem. 262: 6462-6477.
115. Thirumangalathu, R., Krishnan, S., Bondarenko, D., Speed-Ricci, M., Randolph, T. W., Carpenter, J. F., and Brems, D. N. (2007), Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics, Biochemistry 46: 6213-6224.
116. Manzanares, D., Rodriguez-Capote, K., Liu, S., Haines, T., Ramos, Y., Zhao, L., Doherty-Kirby, A., Lajoie, G., and Possmayer, F. (2007), Modification of tryptophan and methionine residues is implicated in the oxidative inactivation of surfactant protein B, Biochemistry 46: 5604-5615.
117. Gray, W. R. (1997), Disulfide bonds between cysteine residues, in Protein Structure: A Practical Guide, Creighton, T. E., ed., IRL Press, pp. 165-186.
118. Wedemeyer, W. J., Welker, E., Narayan, M., and Scheraga, H. A. (2000), Disulfide bonds and protein folding, Biochemistry 39: 4207-4216.
119. David, C., Foley, S., Mavon, C., and Enescu, M. (2008), Reductive unfolding of serum albumins uncovered by Raman spectroscopy, Biopolymers 89: 623-634.
120. Graham, L. and Gallop, P. M. (1994), Covalent protein crosslinks: General detection, quantitation, and characterization via modification with diphenylborinic acid, Anal. Biochem. 217: 298-305.
121. Lorand, L., Hsu, L. K., and Siefring, G. E. (1981), Lens transglutaminase and cataract formation, Proc. Natl. Acad. Sci. USA 78: 1356-1360.
122. Turell, L., Botti, H., Carballal, S., Ferrer-Sueta, G., Souza, J. M., Duran, R., Freeman, B. A., Radi, R., and Alvarez, B. (2008), Reactivity of sulfenic acid in human serum albumin, Biochemistry 47: 358-367.
123. International Conference on Harmonization (1996), Guidance for industry: Q1B. Photostability testing of new drug substances and products; www.ich.org.
124. Kerwin, B. A. and Remmele, R. J., Jr. (2007), Protect from light: Photodegradation and protein biologics, J. Pharm. Sci. 96: 1468-1479.
125. Davies, M. J. and Truscott, R. J. (2001), Photo-oxidation of proteins and its role in cataractogenesis, J. Photochem. Photobiol. B 63: 114-125.
126. Grossweiner, L. I. (1984), Photochemistry of proteins: A review, Curr. Eye Res. 3: 137-144.
127. Duenas, E. T., Keck, R., DeVos, A., Jones, A. J. S., and Cleland, J. L. (2001), Comparison between light induced and chemically induced oxidation of rhVEGF, Pharm. Res. 18: 1455-1460.
128. Wei, Z., Feng, J., Lin, H.-Y., Mullapudi, S., Bishop, E., Tous, G. I., Casas-Finet, J., Hakki, F., Strouse, R., and Schenerman, M. A. (2007), Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus, Anal. Chem. 79: 2797-2805.
129. Lam, X. M., Yang, J. Y., and Cleland, J. L. (1997), Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2, J. Pharm. Sci. 86: 1250-1255.
130. Sysak, P. K., Foote, C. S., and Ching, T.-Y. (1977), Chemistry of singlet oxygen-xxv. Photooxygenation of methionine, Photochem. Photobiol. 26: 19-27.
131. Dalsgaard, T. K., Otzen, D., Nielsen, J. H., and Larsen, L. B. (2007), Changes in structures of milk proteins upon photo-oxidation, J. Agric. Food Chem. 55: 10968-10976.
132. Miller, B. L., Hageman, M. J., Thamann, T. J., Barron, L. B., and Scḧoneich, C. (2003), Solid-state photodegradation of bovine somatotropin (bovine growth hormone): Evidence for tryptophan-mediated photoxidation of disulfide bonds, J. Pharm. Sci. 92: 1698-1709.
133. Scḧoneich, C. (2008), Mechanisms of protein damage induced by cysteine thiyl radical formation, Chem. Res. Toxicol. 21: 1175-1179.
134. Silvester, J. A., Timmins, G. S., and Davies, M. J. (1998), Photodynamically generated bovine serum albumin radicals: Evidence for damage transfer and oxidation at cysteine and tryptophan residues. Free Radical Biol. Med. 24: 754-766.
135. Chu, J. W., Yin, J., Brooks, B. R., Wang, D. I. C., Ricci, M. S., Brems, D. N., and Trout, B. L. (2004), A comprehensive picture of non-site specific oxidation of methionine residues by peroxides in protein pharmaceuticals, J. Pharm. Sci. 93: 3096-3102.
136. Kornfelt, T., Persson, E., and Palm, L. (1999), Oxidation of methionine residues in coagulation Factor VIIa, Arch. Biochem. Biophys. 363: 43-54.
137. Li, T., Chang, B., and Sloey C. (2003), L-Methionine as a Stabilizer for NESP/EPO in HSA-Free Formulations, US Patent application 20,030,104,996.
138. Takruri, H. (1993), Method for the Stabilization of Methionine-Containing Polypeptides, US Patent 5,272,135, Dec. 21, 1993.
139. Yin, J., Chu, J., Ricci, M. S., Brems, D. N., Wang, D. I. C., and Trout, B. L. (2004), Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34, Pharm. Res. 21: 2377-2383.
140. Knepp, V. M., Whatley, J. L., Muchnik, A., and Calderwood, T. S. (1996), Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor, PDA J. Pharm. Sci. Technol. 50: 163-171.
141. Anraku, M., Kouno, Y., Kai, T., Tsurusaki, Y., Yamasaki, K., and Otagiri, M. (2007). The role of N-acetyl-methioninate as a new stabilizer for albumin products, Int. J. Pharm. 329: 19-24.
142. Anraku, M., Tsurusaki, Y., Watanabe, H., Maruyama, T., Kragh-Hansen, U., and Otagiri, M. (2004), Stabilizing mechanisms in commercial albumin preparations: Octanoate and N-acetyl-L-tryptophanate protect human serum albumin against heat and oxidative stress, Biochim. Biophys. Acta 1702: 9-17.
143. Bridgewater, J. D. and Vachet, R. W. (2005), Metal-catalyzed oxidation reactions and mass spectrometry: The roles of ascorbate and different oxidizing agents in determining Cu-protein-binding sites, Anal. Biochem. 341: 122-130.
144. DePaz, R. A., Barnett, C. C., Dale, D. A., Carpenter, J. F., Gaertner, A. L., and Randolph, T. W. (2000), The excluding effects of sucrose on a protein chemical degradation pathway: Methionine oxidation in subtilisin, Arch. Biochem. Biophys. 384: 123-132.
145. Joo, H., Koo, Y., Choi, J., and Chang, C. (2005), Stabilization method of an alkaline protease from inactivation by heat, SDS and hydrogen peroxide, Enzyme Microb. Technol. 36: 766-772.
146. Soenderkaer, S., Carpenter, J. F., Weert, M., Hansen, L. L., Flink, J., and Frokjaar, S. (2004), Effects of sucrose on rFVIIa aggregation and methionine oxidation, Eur. J. Pharm. Sci. 21: 597-606.
147. Yin, J., Chu, J., Ricci, M. S., Brems, D. N., Wang, D. I. C., and Trout, B. L. (2005), Effects of excipients on the hydrogen peroxide-induced oxidation of methionine residues in granulocyte colony-stimulating factor, Pharm. Res. 22: 141-147.
148. Li, S., Patapoff, T. W., Nguyen, T. H., and Borchardt, R. T. (1996), Inhibitory effect of sugars and polyols on the metal-catalyzed oxidation of human relaxin, J. Pharm. Sci. 85: 868-872.
149. Wen, Z., Torraca, G., Yee, C., and Li, G. (2007), Investigation of contaminants in protein pharmaceuticals in pre-filled syringes by multiple micro-spectroscopies, Am. Pharm. Rev. 10(5): 101-107.
150. Markovic, I. (2006), Challenges associated with extractable and/or leachable substances in therapeutic biologic protein products, Am. Pharm. Rev. 9(6): 20-27.
151. Rosenberg, A. S., and Worobec, A. (2004), A risk-based approach to immunogenicity concerns of therapeutic protein products, Part 2: Considering host-specific and productspecific factors impacting immunogenicity, BioPharm (Dec.) 34-40.
152. Yokota, H., Saito, H., Masuoka, K., Kaniwa, H., and Shibanuma, T. (2000), Reversed phase HPLC of Met58 oxidized rhIL-11: Oxidation enhanced by plastic tubes, J. Pharm. Biomed. Anal. 24: 317-324.
153. Uversky, V. N., Yamin, G., Souillac, P. O., Goers, J., Glaser, C. B., and Fink, A. L. (2002), Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro, FEBS Lett. 517: 239-244.
154. Fisher, M. T. and Stadtman, E. R. (1992), Oxidative modification of Escherichia coli glutamine synthetase: Decreases in the thermodynamic stability of protein structure and specific changes in the active site conformation, J. Biol. Chem. 267: 1872-1880.
155. Liu, D., Ren, D., Huang, H., Dankberg, J., Rosenfeld, R., Cocco, M. J., Li, L., Brems, D. N., and Remmele Jr., R. C. (2008), Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation, Biochemistry 47: 5088-5100.
156. Gao, J., Yin, D. H., Yao, Y., Qin, H., Scḧoneich, C., Williams, T. D., and Squier, T. C. (1998), Loss of conformational stability of calmodulin upon methionine oxidation, Biophys. J. 74: 1115-1134.
157. Krishnan, S., Chi, E. Y., Wood, S. J., Kendrick, B. S., Li., C., Garzon-Rodriguez, W., Wypych, J., Randolph, T. W., Narhi, L. O., Biere, A. L., Citron, M., and Carpenter, J. F. (2003), Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis, Biochemistry 42: 829-837.
158. Palmblad, M., Westlind-Danielsson, A., and Bergquist, J. (2002), Oxidation of methionine-35 attenuates formation of amyloid ß-peptide 1-40 oligomers, J. Biol. Chem. 277: 19506-19510.
159. Watson, A. A., Fairlie, D. P., and Craik, D. J. (1998), Solution structure of methionineoxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching? Biochemistry 37: 12700-12706.
160. Steinmetz, M. O., Garcia-Echeverria, C., and Kammerer, R. A. (2005), Design of a coiledcoil-based model peptide system to explore the fundamentals of amyloid formation. Int. J. Pept. Res. Ther. 11: 43-52.
161. Khossravi, M., Shire, S. J., and Borchardt, R. T. (2000), Evidence for the involvement of histadine A(12) in the aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation, Biochemistry 39: 5876-5885.
162. Li, S., Nguyen, T. H., Scḧoneich, C., and Borchardt, R. T. (1995), Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation, Biochemistry 34: 5762-5772.
163. Gaudiano, M. C., Colone, M., Bombelli, C., Chistolini, P., Valvo, L., and Diociaiuti, M. (2005), Early stages of salmon calcitonin aggregation: effect induced by aging and oxidation processes in water and in the presence of model membranes, Biochim. Biophys. Acta 1750: 134-145.
164. Hu, D., Qin, Z., Xue, B., Fink, A. L., and Uversky, V. N. (2008), Effect of methionine oxidation on the structural properties, conformational stability, and aggregation of immunoglobulin light chain LEN, Biochemistry 47: 8665-8677.
165. Horvat, S. and Jakas, A. (2004), Peptide and amino acid glycation: New insights into the Maillard reaction, J. Pept. Sci. 10: 119-137.
166. Ledl, F. and Schleicher, E. (1990), New aspects of the Maillard reaction in foods and the human body, Angew. Chem. Int. Ed Engl. 29: 565-594.
167. Bell, L. N., White, K. L., and Chen, Y. (1998), Maillard reaction in glassy low-moisture solids as affected by buffer type and concentration, J. Food Sci. 63: 785-788.
168. Bell, L. N., Touma, D. E., White, K. L., and Chen, Y. (1998), Glycine loss and Maillard browning as related to the glass transition in a model food system, J. Food Sci. 63: 625-628.
169. Ajandouz, E. H. and Puigserver, A. (1999), Nonenzymatic browning reaction of essential amino acids: Effect of pH on caramelization and Maillard reaction kinetics, J. Agric. Food Chem. 47: 1786-1793.
170. Labuza, T. P., Tannenba, S. R., and Karel, M. (1970), Water content and stability of low-moisture and intermediate-moisture foods, Food Technol. 24: 543-.
171. Schebor, C., del Pilar Buera, M., Karel, M., and Chirife, J. (2000), Color formation due to non-enzymatic browning in amorphous, glassy, anhydrous, model systems, Food Chem. 65: 427-432.
172. Hill, S. A., MacNaughtan, W., Farhot, I. A., Noel, T. R., Parker, R., Ring, S. G., and Whitcombe, M. J. (2005), The effect of thermal history on the Maillard reaction in a glassy matrix, J. Agric. Food Chem. 53: 10213-10218.
173. Kawai, K., Hagiwara, T., Takai, R., and Suzuki, T. (2005), The rate of non-enzymatic browning reaction in model freeze-dried food system in the glassy state, Innov. Food Sci. Emerging Technol. 6: 346-350.
174. Carpenter, J. F., Pikal, M. J., Chang, B. S., and Randolph, T. W. (1997), Rational design of stable lyophilized protein formulations: some practical advice, Pharm. Res. 14: 969-975.
175. Gerrard, J. A. (2002), Aspects of an AGEing chemistry-recent developments concerning the Maillard reaction, Austral J. Chem. 55: 299-310.
176. Zheng, X., Wu, S., and Hancock, W. S. (2006), Glycation of interferon-beta-1b and human serum albumin in a lyophilized glucose formation: Part III: Application of proteomic analysis to the manufacture of biological drugs, Int. J. Pharm. 322: 136-145.
177. Hinton, D. J. S. and Ames, J. M. (2006), Site specificity of glycation and carboxymethylation of bovine serum albumin by fructose, Amino Acids 30: 425-435.
178. Jakas, A., Vinković, M., Smrečki, V., Šporec, M., and Horvat, Š. (2008), Fructose-induced N-terminal glycation of enkephalins and related peptides, J. Pept. Sci. 14: 936-945.
179. Roščić, M. and Horvat, Š. (2006), Transformations of bioactive peptides in the presence of sugars-characterization and stability studies of the adducts generated via the Maillard reaction, Bioorg. Med. Chem. 14: 4933-4943.
180. Bouma, B., Kroon-Batenberg, L. M. J., Wu, Y., Brunjes, B., Posthuma, G., Kranenburg, O., de Groot, P. G., Voest, E. E., and Gebbink, M. F. B. G. (2003), Glycation induces formation of amyloid cross-beta structure in albumin, J. Biol. Chem. 278: 41810-41819.
181. Smales, C. M., Pepper, D. S., and James, D. C. (2001), Protein modifications during antiviral heat bioprocessing and subsequent storage, Biotechnol. Progress 17: 974-978.
182. Smales, C. M., Pepper, D. S., and James, D. C. (2000), Mechanisms of protein modification during model anti-viral heat-treatment bioprocessing of beta-lactoglobulin variant A in the presence of sucrose, Biotechnol. Appl. Biochem. 32: 109-119.
183. Hawe, A. and Friess, W. (2008), Development of HSA-free formulations for a hydrophobic cytokine with improved stability, Eur. J. Pharm. Biopharm. 68: 169-182.
184. Gadgil, H. S., Bondarenko, P. V., Pipes, G., Rehder, D., McAuley, A., Perico, N., Dillon, T., Ricci, M., and Treuheit, M. (2007), The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations, J. Pharm. Sci. 96: 2607-2621.
185. Brady, L. J., Martinez, T., and Balland, A. (2007), Characterization of nonenzymatic glycation on a monoclonal antibody, Anal. Chem. 79: 9403-9413.
186. Kennedy, D. M., Skillen, A. W., and Self, C. H. (1994), Glycation of monoclonalantibodies impairs their ability to bind antigen, Clin. Exp. Immunol. 98: 245-251.
187. Sutthirak, P., Dharmsthiti, S., and Lertsiri, S. (2005), Effect of glycation on stability and kinetic parameters of thermostable glucoamylase from Aspergillus niger, Process Biochem. 40: 2821-2826.
188. Carballal, S., Alvarez, B., Turell, L., Botti, H., Freeman, B. A., and Radi, R. (2007), Sulfenic acid in human serum albumin, Amino Acids 32: 543-551.